MX2022001255A - Metodos y composiciones para la expansion y la citotoxicidad mejoradas de las celulas asesinas naturales. - Google Patents

Metodos y composiciones para la expansion y la citotoxicidad mejoradas de las celulas asesinas naturales.

Info

Publication number
MX2022001255A
MX2022001255A MX2022001255A MX2022001255A MX2022001255A MX 2022001255 A MX2022001255 A MX 2022001255A MX 2022001255 A MX2022001255 A MX 2022001255A MX 2022001255 A MX2022001255 A MX 2022001255A MX 2022001255 A MX2022001255 A MX 2022001255A
Authority
MX
Mexico
Prior art keywords
methods
compositions
cytotoxicity
natural killer
expansion
Prior art date
Application number
MX2022001255A
Other languages
English (en)
Spanish (es)
Inventor
James Barnaby Trager
Ivan Chan
Alexandra Leida Liana Lazetic
Anmol Vohra
Original Assignee
Nkarta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nkarta Inc filed Critical Nkarta Inc
Publication of MX2022001255A publication Critical patent/MX2022001255A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2312—Interleukin-12 (IL-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2318—Interleukin-18 (IL-18)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2022001255A 2019-07-31 2020-07-29 Metodos y composiciones para la expansion y la citotoxicidad mejoradas de las celulas asesinas naturales. MX2022001255A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962881311P 2019-07-31 2019-07-31
US201962932342P 2019-11-07 2019-11-07
PCT/US2020/044033 WO2021021907A1 (en) 2019-07-31 2020-07-29 Methods and compositions for enhanced expansion and cytotoxicity of natural killer cells

Publications (1)

Publication Number Publication Date
MX2022001255A true MX2022001255A (es) 2022-05-10

Family

ID=74229259

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001255A MX2022001255A (es) 2019-07-31 2020-07-29 Metodos y composiciones para la expansion y la citotoxicidad mejoradas de las celulas asesinas naturales.

Country Status (10)

Country Link
US (1) US20220411754A1 (enExample)
EP (1) EP4003379A4 (enExample)
JP (1) JP7724765B2 (enExample)
KR (1) KR20220038439A (enExample)
CN (1) CN114450015A (enExample)
AU (1) AU2020321354A1 (enExample)
CA (1) CA3144724A1 (enExample)
IL (1) IL289902A (enExample)
MX (1) MX2022001255A (enExample)
WO (1) WO2021021907A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3143134T3 (da) 2014-05-15 2021-01-04 Nat Univ Singapore Modificerede, naturlige dræberceller og anvendelser deraf
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
BR112019019917A2 (pt) 2017-03-27 2020-04-22 Nat Univ Singapore receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais
EP3749685A4 (en) 2018-02-09 2021-12-22 National University of Singapore ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY
JP7334985B2 (ja) 2018-04-02 2023-08-29 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
CA3120563A1 (en) 2018-11-26 2020-06-04 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
AU2020288829A1 (en) * 2019-06-04 2021-12-02 Nkarta, Inc. Combinations of engineered natural killer cells and engineered T cells for immunotherapy
US12551530B2 (en) 2020-08-14 2026-02-17 Kite Pharma, Inc. Immune cell function
IL300903A (en) * 2020-09-02 2023-04-01 Nkarta Inc Expansion and enhanced cytotoxicity of natural killer cells and their uses
US20240316102A1 (en) 2021-07-01 2024-09-26 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
AU2022319878A1 (en) * 2021-07-28 2024-01-18 Nkarta, Inc. Selection of optimal cell donors and methods and compositions for enhanced expansion and cytotoxicity of donor cells
CN116236461B (zh) * 2021-12-08 2026-03-24 深圳先进技术研究院 一种氧化还原型纳米颗粒和活细胞载体及其应用
JP2025525439A (ja) 2022-06-30 2025-08-05 インダプタ セラピューティクス インコーポレイテッド 操作されたナチュラルキラー（ｎｋ）細胞と抗体療法との組み合わせおよび関連する方法
EP4649139A1 (en) * 2023-02-01 2025-11-19 Nkarta, Inc. Methods for expanding immune cells and related compositions and uses thereof
WO2025150751A1 (ko) * 2024-01-11 2025-07-17 사회복지법인 삼성생명공익재단 Nk 세포의 활성화 및 증폭용 배양보조세포 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101684456A (zh) * 2008-09-28 2010-03-31 江门罗森生物制药有限公司 一种体外培养条件下扩增人nk细胞的方法
DK3143134T3 (da) * 2014-05-15 2021-01-04 Nat Univ Singapore Modificerede, naturlige dræberceller og anvendelser deraf
HK1245080A1 (zh) * 2014-10-27 2018-08-24 University Of Central Florida Research Foundation, Inc. 自然杀伤细胞的方法和组合物
US20190134095A1 (en) * 2016-05-02 2019-05-09 Cerus Corporation Compositions and methods for improved nk cell therapies
CN106085958A (zh) * 2016-08-04 2016-11-09 英普乐孚生物技术(上海)有限公司 一种nk细胞的制备方法
US10300089B2 (en) * 2016-11-08 2019-05-28 University Of Central Florida Research Foundation, Inc. Methods for high scale therapeutic production of memory NK cells
CA3056591A1 (en) * 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells

Also Published As

Publication number Publication date
CA3144724A1 (en) 2021-02-04
JP2022542399A (ja) 2022-10-03
KR20220038439A (ko) 2022-03-28
US20220411754A1 (en) 2022-12-29
IL289902A (en) 2022-03-01
EP4003379A1 (en) 2022-06-01
JP7724765B2 (ja) 2025-08-18
WO2021021907A1 (en) 2021-02-04
EP4003379A4 (en) 2023-08-30
AU2020321354A1 (en) 2022-03-03
CN114450015A (zh) 2022-05-06

Similar Documents

Publication Publication Date Title
MX2022001255A (es) Metodos y composiciones para la expansion y la citotoxicidad mejoradas de las celulas asesinas naturales.
WO2022120370A3 (en) Methods of engineering immune cells for enhanced potency and persistence and uses of engineered cells in immunotherapy
ZA202103962B (en) Novel composition
PH12020550039A1 (en) Sialyltransferases and their use in producing sialylated oligosaccharides
WO2020168300A8 (en) Modified natural killer (nk) cells for immunotherapy
WO2016201047A8 (en) Crispr/cas-related methods and compositions for improving transplantation
MX2025008210A (es) Microbioreactor de flujo continuo
ZA202004679B (en) Regeneration of genetically modified plants
MX355785B (es) Composicions y metodos para la biosintesis de vainillina o de beta-d-glucosido de vainillina.
WO2017075389A8 (en) Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
MX389322B (es) Metodos para complementar dietas con alto consumo de granos y/o alto valor energetico en rumiantes, mediante la administracion de un bioensamble sintetico de microbios, o cepas purificadas de los mismos
MX339769B (es) Sistemas, metodos y composiciones para optimizar injertos enriquecidos con celulas y tejidos.
WO2017070395A8 (en) Methods of preparing t cells for t cell therapy
NZ703137A (en) Cells for producing recombinant iduronate-2-sulfatase
MY159487A (en) Reduced by-product accumulation for improved production of isobutanol
SG178885A1 (en) Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
MY191370A (en) Production of odd chain fatty acid derivatives in recombinant microbial cells
MX357280B (es) Método sin alimentadoras para cultivo de células madre espermatogonias de bovino y porcino.
TW200943561A (en) Group III-nitride solar cell with graded compositions
MY201637A (en) Natural killer cells and ilc3 cells and uses thereof
WO2017115128A3 (en) Vector-free delivery of gene editing proteins and compositions to cells and tissues
EP4361256A3 (en) Media and methods for enhancing the survival and proliferation of stem cells
SG10201809452RA (en) Cell culture compositions with antioxidants and methods for polypeptide production
WO2020074925A3 (en) Induced pluripotent cell comprising a controllable transgene for conditional immortalisation
MX2022000425A (es) Metodos y composiciones que comprenden un nivel reducido de proteinas de celulas hospedadoras.